PL2134685T3 - Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 - Google Patents

Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1

Info

Publication number
PL2134685T3
PL2134685T3 PL08745934T PL08745934T PL2134685T3 PL 2134685 T3 PL2134685 T3 PL 2134685T3 PL 08745934 T PL08745934 T PL 08745934T PL 08745934 T PL08745934 T PL 08745934T PL 2134685 T3 PL2134685 T3 PL 2134685T3
Authority
PL
Poland
Prior art keywords
nonsubstituted
mcl
inhibitors
indole derivatives
indole
Prior art date
Application number
PL08745934T
Other languages
English (en)
Inventor
Milan Bruncko
Xiaohong Song
Hong Ding
Zhi-Fu Tao
Aaron R Kunzer
Steven W Elmore
Cheol-Min Park
David Madar
Xilu Wang
Andrew J Souers
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PL2134685T3 publication Critical patent/PL2134685T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08745934T 2007-04-16 2008-04-16 Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 PL2134685T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91204907P 2007-04-16 2007-04-16
US94968307P 2007-07-13 2007-07-13
PCT/US2008/060427 WO2008130970A1 (en) 2007-04-16 2008-04-16 7-nonsubstituted indole mcl-1 inhibitors
EP08745934.3A EP2134685B1 (en) 2007-04-16 2008-04-16 7-nonsubstituted indole derivatives as mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
PL2134685T3 true PL2134685T3 (pl) 2016-02-29

Family

ID=39683700

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08745934T PL2134685T3 (pl) 2007-04-16 2008-04-16 Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1

Country Status (11)

Country Link
US (2) US7981888B2 (pl)
EP (1) EP2134685B1 (pl)
JP (2) JP5496876B2 (pl)
CN (1) CN101711235A (pl)
CA (2) CA2951295C (pl)
DK (1) DK2134685T3 (pl)
ES (1) ES2550753T3 (pl)
MX (1) MX2009011210A (pl)
PL (1) PL2134685T3 (pl)
PT (1) PT2134685E (pl)
WO (1) WO2008130970A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2705599T3 (es) * 2007-04-16 2019-03-26 Abbvie Inc Indoles sustituidos en la posición 7 como inhibidores de mcl-1
US8759520B2 (en) 2008-12-08 2014-06-24 Boehringer Ingelheim International Gmbh Compounds for treating cancer
NZ593537A (en) * 2008-12-19 2013-07-26 Genentech Inc Isoquinoline derivatives and methods of use
NZ593536A (en) * 2008-12-19 2013-07-26 Genentech Inc Quinoline derivatives and methods of use
EP3138838A1 (en) 2010-01-29 2017-03-08 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2567698B1 (en) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9926306B2 (en) 2012-03-20 2018-03-27 Dana-Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
CA2922341C (en) 2013-08-28 2022-06-07 Vanderbilt University Substituted indole mcl-1 inhibitors
JP6757312B2 (ja) 2014-03-27 2020-09-16 ヴァンダービルト ユニバーシティー 置換インドールｍｃｌ−１阻害剤
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
ES2803581T3 (es) 2014-10-29 2021-01-28 Walter & Eliza Hall Inst Medical Res Inhibidores de Mcl-1 para su uso en el tratamiento de enfermedades provocadas por neovascularización patológica
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
WO2017075185A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2017075182A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
US11866409B2 (en) * 2015-11-02 2024-01-09 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
AU2017228385B2 (en) * 2016-03-04 2021-11-04 Vanderbilt University Substituted indole Mcl-1 inhibitors
SMT202000249T1 (it) 2016-04-22 2020-07-08 Astrazeneca Ab Inibitori di mcl1 macrociclici per il trattamento di cancro
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JP6910027B2 (ja) * 2017-03-29 2021-07-28 株式会社コーセー チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白剤
WO2018204286A1 (en) * 2017-04-30 2018-11-08 Development Center For Biotechnology An anti-cancer stemness drug
TWI810220B (zh) 2017-11-17 2023-08-01 德商拜耳廠股份有限公司 經取代之巨環吲哚衍生物
AR113886A1 (es) 2017-11-17 2020-06-24 Broad Inst Inc Derivados de indol macrocíclicos
WO2019096905A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
US11447504B2 (en) 2017-11-17 2022-09-20 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
US20210253598A1 (en) 2017-11-17 2021-08-19 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
US11286263B2 (en) 2017-11-17 2022-03-29 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives
AU2019347963A1 (en) * 2018-09-30 2021-05-27 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method therefor and application thereof in medicine
TWI749404B (zh) * 2018-11-22 2021-12-11 大陸商蘇州亞盛藥業有限公司 作為mcl-1抑制劑的大環吲哚
US12338250B2 (en) 2019-05-17 2025-06-24 The Broad Institute, Inc. Methods of preparing macrocyclic indoles
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
MX2022006179A (es) 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022006180A (es) 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
TW202134213A (zh) 2019-11-29 2021-09-16 日商小野藥品工業股份有限公司 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
WO2021197295A1 (zh) * 2020-03-30 2021-10-07 江苏恒瑞医药股份有限公司 一种吲哚类大环衍生物的结晶形式及其制备方法
KR20230017823A (ko) 2020-05-29 2023-02-06 얀센 파마슈티카 엔.브이. Mcl-1의 억제제로서의 마크로사이클릭 7-피라졸-5-일-인돌 유도체
AU2021291056A1 (en) 2020-06-19 2023-02-23 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of MCL-1
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632805A (en) 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
FR2187318B1 (pl) 1972-06-08 1975-06-20 Delalande Sa
US4994477A (en) 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
ES2208935T3 (es) * 1996-08-01 2004-06-16 Merckle Gmbh Acidos acil-pirrol-dicarboxilicos y acidos acil-indol-dicarboxilicos, asi como sus derivados como inhibidores de la fosfolipasa a2 citosolica.
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
KR100615341B1 (ko) 1998-11-27 2006-08-25 미쓰비시 가가꾸 가부시키가이샤 말레산 무수물의 제조방법
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000626D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
JP2004529855A (ja) * 2000-10-10 2004-09-30 スミスクライン ビーチャム コーポレーション 置換インドール類、そのような置換インドール類を含む医薬組成物及びＰＰＡＲ−γ結合剤としてのそれらの使用
DE10153346A1 (de) 2001-10-29 2004-04-22 Grünenthal GmbH Substituierte Indole
CN100348569C (zh) * 2001-11-30 2007-11-14 伯哈姆学院 癌细胞中编程性细胞死亡的诱导
JP2005519915A (ja) * 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
DE60328675D1 (de) * 2002-04-23 2009-09-17 Aventis Pharma Inc 3-(substitutierte amino)-1h-indole-2-carbonsäureester und 3-(substitutierte amino)-benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
WO2004092346A2 (en) * 2003-04-15 2004-10-28 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
DE602005014233D1 (de) * 2004-06-18 2009-06-10 Biolipox Ab Zur behandlung von entzündungen geeignete indole
CN101006053A (zh) * 2004-06-18 2007-07-25 比奥里波克斯公司 用于治疗炎症的吲哚
US20080188473A1 (en) * 2004-06-18 2008-08-07 Kristofer Olofsson Indoles Useful in the Treatment of Inflammation
WO2006041961A1 (en) * 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
ATE501119T1 (de) * 2005-01-19 2011-03-15 Biolipox Ab Entzündungshemmende indol-derivate
JP2008527030A (ja) * 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
JP5193861B2 (ja) * 2005-07-07 2013-05-08 アボット・ラボラトリーズ アポトーシス促進剤
PE20080767A1 (es) * 2006-08-31 2008-08-08 Smithkline Beecham Corp Derivados de acido 1-indol-2-carboxilico como moduladores de ppar
ES2705599T3 (es) 2007-04-16 2019-03-26 Abbvie Inc Indoles sustituidos en la posición 7 como inhibidores de mcl-1
NZ593536A (en) 2008-12-19 2013-07-26 Genentech Inc Quinoline derivatives and methods of use
NZ593537A (en) 2008-12-19 2013-07-26 Genentech Inc Isoquinoline derivatives and methods of use

Also Published As

Publication number Publication date
JP5496876B2 (ja) 2014-05-21
JP2010524955A (ja) 2010-07-22
ES2550753T3 (es) 2015-11-12
WO2008130970A1 (en) 2008-10-30
CA2682354C (en) 2016-12-13
CA2951295A1 (en) 2008-10-30
EP2134685A1 (en) 2009-12-23
PT2134685E (pt) 2015-11-25
CA2951295C (en) 2020-04-28
MX2009011210A (es) 2009-10-30
CA2682354A1 (en) 2008-10-30
JP2014129396A (ja) 2014-07-10
JP5895011B2 (ja) 2016-03-30
US20090124616A1 (en) 2009-05-14
DK2134685T3 (en) 2015-12-07
CN101711235A (zh) 2010-05-19
US20110263599A1 (en) 2011-10-27
US7981888B2 (en) 2011-07-19
US8853209B2 (en) 2014-10-07
EP2134685B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
PT2134685E (pt) Derivados de índole não substituídos na posição 7 como inibidores de mcl-1
IL201432A0 (en) 7 - substituted indole mcl - 1 inhibitors
ZA200904138B (en) Substituted spirochromanone derivatives as acc inhibitors
IL207684A0 (en) Substituted indole derivatives
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
PL2215075T3 (pl) Pochodne chinolinonu jako inhibitory PARP
ZA201104361B (en) Substituted dioxopiperidinyl phthalimide derivatives
IL208203A0 (en) Heterocyclic derivatives
IL202020A0 (en) Spiroindolinone derivatives
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
GB0905328D0 (en) Indole derivatives
AP2743A (en) Macrocyclic indole derivatives useful as hepatitisC virus inhibitors
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
IL202034A0 (en) Heterocyclic indazole derivatives
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
IL207225A0 (en) Indazole derivatives
IL211290A0 (en) New 2-amidothiadiazole derivatives
IL202612A0 (en) Compositions comprising tryptophan hydroxylase inhibitors
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA200905265B (en) Indole derivatives
ZA201002580B (en) Heterocyclic derivatives